Annals of internal medicine|2026|Boye K et al.
PMID: 41911554
14102 studies
Tirzepatide, a novel dual glucagon inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the management of type 2 diabetes mellitus (T2DM) and chronic weight management. There are no current case reports on tirzepa…
INTRODUCTION: Tirzepatide has demonstrated cardiovascular and metabolic benefits in the general population; however, evidence in post-transplant patients is very limited. The aim of this systematic review and meta-analysis is to evaluate the safety a…
Tirzepatide (TZP), a novel dual agonist of glucagon-like peptide (GLP)-1/glucose-dependent insulinotropic polypeptide (GIP) receptors (GLP-1R/GIPR), has been shown to reduce cardiovascular (CV) risk in patients with diabetes or obesity. This study in…
IMPORTANCE: The dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide was noninferior to a GLP-1 agonist, dulaglutide, for effects on the composite outcome of cardiovascular death, myocardial…
OBJECTIVE: Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult part…
OBJECTIVE: This study compared weight-loss outcomes in patients prescribed tirzepatide by weight-loss status and assessed results among patients transitioning from semaglutide. METHODS: This retrospective cohort study analyzed 6-month weight-loss out…
AIMS: This work aimed to contextualize glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Admi…
Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicit…
Dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have emerged as a novel therapeutic class with potential relevance for cardiovascular prevention, particularly in the context of obesity and…
Tirzepatide is a synthetic polypeptide classified as glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist. It stimulates insulin secretion from the pancreas and helps lower blood sugar levels in patients with type 2 d…
BACKGROUND: Tirzepatide, a dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity, carries a theoretical risk of pancreatitis. Whether risk varies by dose is uncertain. METHODS: Randomised controlled trials (RCTs) reporting outcomes from Tir…
INTRODUCTION: Tirzepatide, a dual GLP-1/GIP receptor agonist, is recently approved for the treatment of type 2 diabetes and obesity in adults. Melanocortin-4-receptor (MC4R) deficiency is the most common monogenic cause of obesity and presents with h…
[This corrects the article DOI: 10.1371/journal.pone.0285197.].
SUMMARY: We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide. Although tirzepatide h…
OBJECTIVE: In prespecified analyses, the treatment effect for MACE of tirzepatide compared with imputed placebo was estimated using SURPASS-CVOT and REWIND data. RESEARCH DESIGN AND METHODS: The indirect comparison with placebo was conducted for prim…
AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparab…